Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Blood-brain barrier (BBB) leakage and brain edema is a critical part of stroke pathophysiology. In this mini-review, we briefly survey the potential role of matrix metalloproteinases (MMPs) in BBB dysfunction. A large body of data in both experimental models as well as clinical patient populations suggests that MMPs may disrupt BBB permeability and interfere with cell-cell signaling in the neurovascular unit. Hence, ongoing efforts are underway to validate MMPs as potential biomarkers in stroke as well as pursue MMP blockers as therapeutic opportunities. Because BBB perturbations may also occur in neurodegeneration, MMPs and associated neurovascular unit mechanisms may also be potential targets in a broader range of CNS disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“But BBB disturbances may also be important in other CNS disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis etc [16].”
BackgroundNeuronal replacement from endogenous precursors in the adult brain after stroke
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., & Lindvall, O. (2002) · Nature Medicine · doi:10.1038/nm747 · Cited by 2,799 · cited 1×
“original rostral migratory stream towards damaged brain [42].”
BackgroundMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004 · cited 2×
“Matrix proteolysis and BBB disruption was reduced in knockout mice lacking MMP-9 [23].”
BackgroundSelf-citationS-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., & Lipton, S. A. (2002) · Science · doi:10.1126/science.1073634 · Cited by 950
Metalloproteinases: Mediators of Pathology and Regeneration in the CNS
Yong, V. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1807 · Cited by 582 · cited 1×
“MMPs comprise a large family of extracellular zinc endopeptidases [14].”
BackgroundMatrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory
Nagy, V., Bozdagi, O., Matynia, A., Balcerzyk, M., Okulski, P., Dzwonek, J., Costa, R. M., Silva, A. J., Kaczmarek, L., & Huntley, G. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4359-05.2006 · Cited by 499
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Multiphasic roles for matrix metalloproteinases after stroke
ROSELL, A., & LO, E. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.001 · Cited by 215 · cited 1×
“But during delayed phases of stroke recovery, MMPs may play surprisingly beneficial roles [36, 37].”
BackgroundSelf-citationAstrocytes protect oligodendrocyte precursor cells via MEK/ERK and PI3K/Akt signaling
Arai, K., & Lo, E. H. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22256 · Cited by 101 · cited 1×
“Cerebral endothelial cells and astrocytes also produce may trophic factors that sustain and protect oligodendrocyte precursor cells against injury [34, 35].”
BackgroundSelf-citation
Cited by
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Pathogenesis of Brain Edema and Investigation into Anti-Edema Drugs
Michinaga, S., & Koyama, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16059949 · Cited by 339
“Although MMPs support the repair of damaged nerve tissues by promoting angiogenesis as VEGFs do [119], their excessive action disrupts the integrity of vascular endothelial cells by degrading the basal lamina around brain microvessels, resulting in BBB hyperpermeability [120].”
BackgroundRivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Zhang, H.-T., Zhang, P., Gao, Y., Li, C.-L., Wang, H.-J., Chen, L.-C., Feng, Y., Li, R.-Y., Li, Y.-L., & Jiang, C.-L. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5974 · Cited by 101
“Several studies have suggested a strong relationship between the induction of MMP-2 and MMP-9 and brain edema following cerebral ischemic injury (10-12), indicating that MMP-2 and MMP-9 may be important targets to prevent edema complications following cerebral ischemia.”
BackgroundInfluential
Metadata
- Authors
- Hae Seo, J., Guo, S., Lok, J., Navaratna, D., J. Whalen, M., Kim, K.-W., & H. Lo, E.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-08-01
- Volume
- 18
- Issue
- 25
- Pages
- 3645-3648
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2028139742
- Cited by
- 79
- References
- 11
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier. https://app.cochat.ai/papers/10.2174/138161212802002742
- The paper
- Hae Seo, J., Guo, S., Lok, J., Navaratna, D., J. Whalen, M., Kim, K.-W., & H. Lo, E. (2012). Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier. Current Pharmaceutical Design. https://doi.org/10.2174/138161212802002742
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.